House Bill No. [insert number] aims to expand health insurance coverage for injectable medications that improve glucose levels or assist with weight loss. The bill enacts a new section, R.S. 22:1028.7, which defines key terms such as "body mass index," "health coverage plan," "injectable drug," and "obesity." It mandates that health coverage plans issued or renewed in Louisiana must provide coverage for these injectable drugs if they are FDA-approved, prescribed by a licensed healthcare provider for conditions like prediabetes, gestational diabetes, or obesity, and included on the insurer's formulary. The bill also allows for the application of annual deductibles, coinsurance, and copayment provisions, as well as prior authorization requirements.

Additionally, the proposed law stipulates that health coverage plans may require ongoing certification of medical necessity from healthcare providers for continued treatment and may mandate participation in lifestyle management programs if available. The provisions of this bill will apply to new policies, contracts, or health coverage plans effective on or after January 1, 2026, with existing plans required to conform by their renewal date, but no later than January 1, 2027. The bill will take effect upon the governor's signature or after the specified period for gubernatorial action.